Anebulo appoints Kenneth Cundy as CSO; $350K salary, options, milestone vesting

Anebulo Pharmaceuticals, Inc.

Dr. Cundy appointed CSO effective May 20, 2022; base salary $350,000, annual bonus up to 30%.
Receives option for 233,446 shares vesting quarterly over 4 years.
Additional option for 116,273 shares vests upon FDA approval of lead candidate ANEB-001.
Severance: 9 months' base salary plus COBRA for up to 12 months if terminated without cause.
Cundy previously CSO at CohBar and XenoPort; coinventor of tenofovir and Nanocrystal technology.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kenneth C. Cundy

Chief Scientific Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2022-05-20
Filed: May 24, 2022, 7:59 PM ET

On May 24, 2022, Anebulo Pharmaceuticals, Inc. announced that Kenneth C. Cundy has been appointed as the Chief Scientific Officer of our company effective May 20, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth C. Cundy was appointed as Chief Scientific Officer at Anebulo Pharmaceuticals, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

On May 24, 2022, Anebulo Pharmaceuticals, Inc. announced that Kenneth C. Cundy has been appointed as the Chief Scientific Officer of our company effective May 20, 2022.

View on SEC.gov

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-014942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.